|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000235568 |
Summary for NFAM1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000235568 | Gene symbol | NFAM1 |
| Gene name | NFAT activating protein with ITAM motif 1 | |
| HGNC | 29872 | |
| Entrez ID | 150372 | |
| Gene type | protein_coding | |
| Synonyms | NFAM1|CNAIP | |
| UniProtAcc | Q8NET5 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for NFAM1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NFAM1 | 7.32e+02 | -1.01e+00 | 2.99e-01 | -3.39e+00 | 6.93e-04 | 8.63e-03 | BRCA |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NFAM1 | 7.61e+02 | 1.69e+00 | 2.51e-01 | 6.73e+00 | 1.68e-11 | 2.59e-10 | THCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for NFAM1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for NFAM1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg17568996 | chr22:42432119 | CGI:chr22:42368383-42369242 | promoter,gene body | 4.23e-01 | 5.89e-01 | -2.41e+00 | 1.58e-02 | 3.19e-02 | -1.67e-01 |
| BRCA | cg01383955 | chr22:42432441 | CGI:chr22:42368383-42369242 | promoter | 6.17e-01 | 7.55e-01 | -2.37e+00 | 1.77e-02 | 3.34e-02 | -1.38e-01 |
| LIHC | cg03365751 | chr22:42432380 | CGI:chr22:42368383-42369242 | UTR,promoter,exon,gene body | 4.86e-01 | 3.71e-01 | 4.03e+00 | 5.68e-05 | 4.57e-04 | 1.15e-01 |
| LIHC | cg22472304 | chr22:42433491 | CGI:chr22:42368383-42369242 | promoter | 6.62e-01 | 5.58e-01 | 4.48e+00 | 7.33e-06 | 8.36e-05 | 1.04e-01 |
| KIRP | cg22472304 | chr22:42433491 | CGI:chr22:42368383-42369242 | promoter | 6.33e-01 | 5.33e-01 | 3.65e+00 | 2.59e-04 | 1.71e-03 | 1.00e-01 |
| SARC | cg03365751 | chr22:42432380 | CGI:chr22:42368383-42369242 | UTR,promoter,exon,gene body | 4.25e-01 | 3.10e-01 | 2.96e+00 | 3.08e-03 | 8.13e-03 | 1.14e-01 |
| SARC | cg09335713 | chr22:42432412 | CGI:chr22:42368383-42369242 | promoter | 4.46e-01 | 3.21e-01 | 3.43e+00 | 6.11e-04 | 2.36e-03 | 1.25e-01 |
| SARC | cg27098470 | chr22:42432405 | CGI:chr22:42368383-42369242 | promoter | 4.68e-01 | 3.50e-01 | 3.29e+00 | 1.01e-03 | 3.52e-03 | 1.19e-01 |
| SARC | cg07264666 | chr22:42432409 | CGI:chr22:42368383-42369242 | promoter | 5.18e-01 | 3.96e-01 | 3.32e+00 | 9.13e-04 | 3.25e-03 | 1.22e-01 |
| SARC | cg01383955 | chr22:42432441 | CGI:chr22:42368383-42369242 | promoter | 4.19e-01 | 3.05e-01 | 3.08e+00 | 2.04e-03 | 5.99e-03 | 1.14e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg03365751 | chr22:42432380 | CGI:chr22:42368383-42369242 | UTR,promoter,exon,gene body | 4.82e-01 | 5.92e-01 | -3.76e+00 | 1.68e-04 | 3.22e-04 | -1.10e-01 |
| KIRC | cg27098470 | chr22:42432405 | CGI:chr22:42368383-42369242 | promoter | 5.57e-01 | 6.63e-01 | -4.21e+00 | 2.51e-05 | 6.08e-05 | -1.06e-01 |
| KIRC | cg01383955 | chr22:42432441 | CGI:chr22:42368383-42369242 | promoter | 4.85e-01 | 6.57e-01 | -4.81e+00 | 1.53e-06 | 5.26e-06 | -1.72e-01 |
| KIRC | cg07044422 | chr22:42432510 | CGI:chr22:42368383-42369242 | promoter | 6.22e-01 | 7.72e-01 | -6.26e+00 | 3.82e-10 | 6.10e-09 | -1.50e-01 |
| LUAD | cg07044422 | chr22:42432510 | CGI:chr22:42368383-42369242 | promoter | 5.80e-01 | 4.74e-01 | 4.02e+00 | 5.75e-05 | 1.77e-04 | 1.06e-01 |
| HNSC | cg01383955 | chr22:42432441 | CGI:chr22:42368383-42369242 | promoter | 5.28e-01 | 4.14e-01 | 2.97e+00 | 2.98e-03 | 4.59e-03 | 1.13e-01 |
| LUSC | cg03365751 | chr22:42432380 | CGI:chr22:42368383-42369242 | UTR,promoter,exon,gene body | 5.39e-01 | 2.82e-01 | 3.85e+00 | 1.19e-04 | 7.52e-04 | 2.57e-01 |
| LUSC | cg09335713 | chr22:42432412 | CGI:chr22:42368383-42369242 | promoter | 5.75e-01 | 3.42e-01 | 3.79e+00 | 1.52e-04 | 8.45e-04 | 2.33e-01 |
| LUSC | cg27098470 | chr22:42432405 | CGI:chr22:42368383-42369242 | promoter | 5.97e-01 | 3.78e-01 | 3.78e+00 | 1.58e-04 | 8.61e-04 | 2.19e-01 |
| LUSC | cg07264666 | chr22:42432409 | CGI:chr22:42368383-42369242 | promoter | 6.59e-01 | 4.71e-01 | 3.74e+00 | 1.84e-04 | 9.29e-04 | 1.88e-01 |
| LUSC | cg17568996 | chr22:42432119 | CGI:chr22:42368383-42369242 | promoter,gene body | 4.27e-01 | 1.86e-01 | 3.64e+00 | 2.77e-04 | 1.16e-03 | 2.40e-01 |
| LUSC | cg01383955 | chr22:42432441 | CGI:chr22:42368383-42369242 | promoter | 5.57e-01 | 2.89e-01 | 3.81e+00 | 1.39e-04 | 8.07e-04 | 2.67e-01 |
| LUSC | cg07044422 | chr22:42432510 | CGI:chr22:42368383-42369242 | promoter | 5.93e-01 | 4.71e-01 | 3.04e+00 | 2.38e-03 | 4.73e-03 | 1.22e-01 |
| LUSC | cg22472304 | chr22:42433491 | CGI:chr22:42368383-42369242 | promoter | 6.84e-01 | 8.06e-01 | -2.80e+00 | 5.07e-03 | 8.24e-03 | -1.23e-01 |
| LUSC | cg03017264 | chr22:42433742 | CGI:chr22:42368383-42369242 | promoter | 7.16e-01 | 9.10e-01 | -3.25e+00 | 1.17e-03 | 2.89e-03 | -1.94e-01 |
| BLCA | cg22472304 | chr22:42433491 | CGI:chr22:42368383-42369242 | promoter | 5.55e-01 | 8.14e-01 | -4.18e+00 | 2.94e-05 | 1.76e-04 | -2.59e-01 |
| BLCA | cg03017264 | chr22:42433742 | CGI:chr22:42368383-42369242 | promoter | 6.15e-01 | 8.58e-01 | -3.43e+00 | 5.97e-04 | 1.52e-03 | -2.42e-01 |
| LIHC | cg03365751 | chr22:42432380 | CGI:chr22:42368383-42369242 | UTR,promoter,exon,gene body | 3.71e-01 | 4.83e-01 | -2.33e+00 | 2.00e-02 | 2.24e-02 | -1.12e-01 |
| LIHC | cg27098470 | chr22:42432405 | CGI:chr22:42368383-42369242 | promoter | 4.29e-01 | 5.85e-01 | -2.72e+00 | 6.55e-03 | 8.37e-03 | -1.56e-01 |
| LIHC | cg07264666 | chr22:42432409 | CGI:chr22:42368383-42369242 | promoter | 5.13e-01 | 6.40e-01 | -2.28e+00 | 2.26e-02 | 2.50e-02 | -1.27e-01 |
| LIHC | cg07044422 | chr22:42432510 | CGI:chr22:42368383-42369242 | promoter | 5.12e-01 | 6.41e-01 | -3.80e+00 | 1.43e-04 | 2.84e-04 | -1.29e-01 |
| LIHC | cg07464578 | chr22:42432940 | CGI:chr22:42368383-42369242 | promoter | 7.29e-01 | 8.92e-01 | -4.71e+00 | 2.47e-06 | 8.09e-06 | -1.63e-01 |
| LIHC | cg22472304 | chr22:42433491 | CGI:chr22:42368383-42369242 | promoter | 5.58e-01 | 8.00e-01 | -5.38e+00 | 7.37e-08 | 4.08e-07 | -2.42e-01 |
| KIRP | cg27098470 | chr22:42432405 | CGI:chr22:42368383-42369242 | promoter | 6.99e-01 | 5.93e-01 | 3.68e+00 | 2.36e-04 | 5.37e-04 | 1.06e-01 |
| ESCA | cg17568996 | chr22:42432119 | CGI:chr22:42368383-42369242 | promoter,gene body | 4.53e-01 | 2.51e-01 | 2.71e+00 | 6.73e-03 | 3.51e-02 | 2.03e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg03365751 | chr22:42432380 | CGI:chr22:42368383-42369242 | UTR,promoter,exon,gene body | 5.89e-01 | 4.14e-01 | 9.66e+00 | 4.64e-22 | 3.00e-21 | 1.75e-01 |
| BRCA | cg09335713 | chr22:42432412 | CGI:chr22:42368383-42369242 | promoter | 6.26e-01 | 4.92e-01 | 8.70e+00 | 3.30e-18 | 1.54e-17 | 1.35e-01 |
| BRCA | cg27098470 | chr22:42432405 | CGI:chr22:42368383-42369242 | promoter | 6.51e-01 | 4.90e-01 | 9.53e+00 | 1.59e-21 | 9.82e-21 | 1.61e-01 |
| BRCA | cg07264666 | chr22:42432409 | CGI:chr22:42368383-42369242 | promoter | 7.09e-01 | 5.69e-01 | 9.51e+00 | 1.83e-21 | 1.12e-20 | 1.41e-01 |
| BRCA | cg17568996 | chr22:42432119 | CGI:chr22:42368383-42369242 | promoter,gene body | 4.23e-01 | 1.90e-01 | 9.60e+00 | 8.31e-22 | 5.25e-21 | 2.33e-01 |
| BRCA | cg01383955 | chr22:42432441 | CGI:chr22:42368383-42369242 | promoter | 6.17e-01 | 3.78e-01 | 1.09e+01 | 1.38e-27 | 1.52e-26 | 2.39e-01 |
| BRCA | cg07044422 | chr22:42432510 | CGI:chr22:42368383-42369242 | promoter | 6.55e-01 | 4.80e-01 | 1.11e+01 | 9.01e-29 | 1.13e-27 | 1.75e-01 |
| BRCA | cg22472304 | chr22:42433491 | CGI:chr22:42368383-42369242 | promoter | 7.93e-01 | 6.88e-01 | 7.37e+00 | 1.66e-13 | 5.40e-13 | 1.05e-01 |
| KIRC | cg03017264 | chr22:42433742 | CGI:chr22:42368383-42369242 | promoter | 8.44e-01 | 7.32e-01 | 2.84e+00 | 4.48e-03 | 1.03e-02 | 1.13e-01 |
| HNSC | cg03017264 | chr22:42433742 | CGI:chr22:42368383-42369242 | promoter | 5.98e-01 | 4.53e-01 | 1.99e+00 | 4.65e-02 | 4.73e-02 | 1.46e-01 |
| BLCA | cg27098470 | chr22:42432405 | CGI:chr22:42368383-42369242 | promoter | 5.54e-01 | 4.53e-01 | 1.98e+00 | 4.81e-02 | 4.85e-02 | 1.00e-01 |
| BLCA | cg17568996 | chr22:42432119 | CGI:chr22:42368383-42369242 | promoter,gene body | 3.50e-01 | 2.34e-01 | 2.04e+00 | 4.12e-02 | 4.37e-02 | 1.16e-01 |
Top |
Exon skipping events with PSI in TCGA for NFAM1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for NFAM1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| KIRC | NFAM1-001 | chr22_42383533_- | 3.75e-01 | 4.15e-01 | -2.44e+00 | 1.46e-02 | 4.41e-02 | -4.00e-02 |
| LUAD | NFAM1-001 | chr22_42383570_- | 1.36e-01 | 1.93e-01 | -2.00e+00 | 4.55e-02 | 4.83e-02 | -5.76e-02 |
| LGG | NFAM1-001 | chr22_42383583_- | 2.57e-01 | 1.96e-01 | 2.26e+00 | 2.39e-02 | 4.68e-02 | 6.06e-02 |
| THCA | NFAM1-001 | chr22_42383505_- | 2.47e-01 | 2.73e-01 | -2.38e+00 | 1.71e-02 | 4.91e-02 | -2.67e-02 |
| THCA | NFAM1-001 | chr22_42383533_- | 3.87e-01 | 3.36e-01 | 2.13e+00 | 3.33e-02 | 4.91e-02 | 5.08e-02 |
| HNSC | NFAM1-001 | chr22_42383505_- | 2.93e-01 | 2.45e-01 | 2.30e+00 | 2.13e-02 | 4.27e-02 | 4.81e-02 |
| BLCA | NFAM1-001 | chr22_42381263_- | 3.90e-01 | 1.76e-01 | 2.95e+00 | 3.18e-03 | 4.21e-02 | 2.14e-01 |
| BLCA | NFAM1-001 | chr22_42383496_- | 1.24e-01 | 1.90e-01 | -1.98e+00 | 4.72e-02 | 4.98e-02 | -6.63e-02 |
| BLCA | NFAM1-001 | chr22_42383583_- | 2.26e-01 | 2.96e-01 | -2.64e+00 | 8.24e-03 | 4.65e-02 | -7.08e-02 |
| SARC | NFAM1-001 | chr22_42381370_- | 2.34e-01 | 1.74e-01 | 2.34e+00 | 1.93e-02 | 4.85e-02 | 6.00e-02 |
| PAAD | NFAM1-001 | chr22_42383495_- | 2.73e-01 | 1.68e-01 | 3.36e+00 | 7.80e-04 | 4.66e-02 | 1.05e-01 |
| GBM | NFAM1-001 | chr22_42383647_- | 2.19e-01 | 1.60e-01 | 2.35e+00 | 1.90e-02 | 4.96e-02 | 5.91e-02 |
| DLBC | NFAM1-001 | chr22_42381238_- | 2.74e-01 | 1.70e-01 | 2.83e+00 | 4.65e-03 | 4.78e-02 | 1.04e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| LUSC | NFAM1-001 | chr22_42383534_- | 2.93e-01 | 2.24e-01 | 2.98e+00 | 2.84e-03 | 8.87e-03 | 6.89e-02 |
| LUSC | NFAM1-001 | chr22_42383647_- | 2.06e-01 | 1.44e-01 | 3.22e+00 | 1.26e-03 | 5.58e-03 | 6.19e-02 |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| BRCA | NFAM1-001 | chr22_42383631_- | 6.03e-01 | 6.69e-01 | -1.97e+00 | 4.84e-02 | 4.88e-02 | -6.61e-02 |
| LUSC | NFAM1-001 | chr22_42381099_- | 6.28e-01 | 5.10e-01 | 2.15e+00 | 3.12e-02 | 3.89e-02 | 1.18e-01 |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for NFAM1 |
| TFs related to NFAM1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | MYC | NFAM1 | 3.71e+00 | 1.42e-02 | 4.82e+00 | 9.80e-01 | Female-biased |
| BRCA | NR1H4 | NFAM1 | 2.83e+00 | 3.95e-03 | 4.33e+00 | 9.82e-01 | Female-biased |
| BRCA | PATZ1 | NFAM1 | 3.01e+00 | 6.08e-03 | 4.37e+00 | 9.81e-01 | Female-biased |
| BRCA | PLAGL2 | NFAM1 | 3.80e+00 | 7.09e-03 | 5.13e+00 | 9.90e-01 | Female-biased |
| BRCA | ZIC2 | NFAM1 | 3.31e+00 | 9.24e-03 | 4.55e+00 | 9.82e-01 | Female-biased |
| BRCA | ZIC4 | NFAM1 | 3.22e+00 | 8.26e-03 | 4.49e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF331 | NFAM1 | 3.41e+00 | 5.43e-03 | 4.82e+00 | 9.89e-01 | Female-biased |
| BRCA | ZNF415 | NFAM1 | 3.21e+00 | 8.66e-03 | 4.46e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF563 | NFAM1 | 3.14e+00 | 7.62e-03 | 4.43e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF594 | NFAM1 | 3.35e+00 | 1.03e-02 | 4.55e+00 | 9.80e-01 | Female-biased |
| BRCA | ZNF816 | NFAM1 | 3.19e+00 | 6.47e-03 | 4.54e+00 | 9.84e-01 | Female-biased |
| NFAM1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for NFAM1 |
| RBPs related to ES in NFAM1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| NFAM1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000235568 | LINC00944,hsa-mir-326,NFAM1 | Male-specific ceRNA | TCGA-KICH |
| ENSG00000235568 | AL031733.2,hsa-mir-326,NFAM1 | Male-specific ceRNA | TCGA-KICH |
| ENSG00000235568 | AL360270.3,hsa-mir-326,NFAM1 | Male-specific ceRNA | TCGA-KICH |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12159685 | chr22:37788646:G:A | - | -0.231506408045823 | 0.0303380251447981 | PCPG | Female-baised eQTL |
| rs56765854 | chr22:48379232:G:A | - | 0.164039967274225 | 0.0328105992724614 | PCPG | Female-baised eQTL |
| rs57948605 | chr22:48379617:G:A | - | 0.164039967274225 | 0.0328105992724614 | PCPG | Female-baised eQTL |
| rs5994813 | chr22:33933337:T:C | - | 0.192003399549227 | 0.00867058174498098 | KIRP | Female-baised eQTL |
| rs5754745 | chr22:33887548:A:C | - | -0.260023641242791 | 6.32944652236607e-05 | BLCA | Female-baised eQTL |
| rs7292199 | chr22:32785589:T:C | - | 0.238980299155366 | 7.78175291860516e-05 | BLCA | Female-baised eQTL |
| rs62232902 | chr22:32798176:C:A | - | 0.22954959256167 | 0.000165968773846882 | BLCA | Female-baised eQTL |
| rs62232903 | chr22:32803376:G:A | - | 0.229157057729643 | 0.000179228682009377 | BLCA | Female-baised eQTL |
| rs2285122 | chr22:44841690:C:G | - | 0.214094817163771 | 0.000372711041020351 | BLCA | Female-baised eQTL |
| rs2285119 | chr22:44840733:G:A | - | 0.213013664173852 | 0.00045533748177544 | BLCA | Female-baised eQTL |
| rs5766084 | chr22:44838525:C:A | - | 0.204716633245687 | 0.000937989325494717 | BLCA | Female-baised eQTL |
| rs4823393 | chr22:44838859:A:G | - | 0.19355403472635 | 0.00111748890241362 | BLCA | Female-baised eQTL |
| rs4823261 | chr22:44838875:A:G | - | 0.19355403472635 | 0.00111748890241362 | BLCA | Female-baised eQTL |
| rs62232922 | chr22:32844047:G:A | - | 0.206529533327064 | 0.0011185937217452 | BLCA | Female-baised eQTL |
| rs12168216 | chr22:32850990:T:G | - | 0.19565106024966 | 0.00224972644869198 | BLCA | Female-baised eQTL |
| rs12165359 | chr22:32853284:C:T | - | 0.19565106024966 | 0.00224972644869198 | BLCA | Female-baised eQTL |
| rs9619317 | chr22:32902428:C:A | - | 0.208172730391401 | 0.00239144989876257 | BLCA | Female-baised eQTL |
| rs62234176 | chr22:32903611:C:A | - | 0.208172730391401 | 0.00239144989876257 | BLCA | Female-baised eQTL |
| rs62234177 | chr22:32903891:C:T | - | 0.208172730391401 | 0.00239144989876257 | BLCA | Female-baised eQTL |
| rs13433590 | chr22:32906907:T:C | - | 0.208172730391401 | 0.00239144989876257 | BLCA | Female-baised eQTL |
| rs62234178 | chr22:32910036:C:T | - | 0.208172730391401 | 0.00239144989876257 | BLCA | Female-baised eQTL |
| rs9619315 | chr22:32890039:A:G | - | 0.207403061948876 | 0.0027092749277305 | BLCA | Female-baised eQTL |
| rs58811278 | chr22:32891108:C:T | - | 0.207403061948876 | 0.0027092749277305 | BLCA | Female-baised eQTL |
| rs61027525 | chr22:32892476:A:G | - | 0.207403061948876 | 0.0027092749277305 | BLCA | Female-baised eQTL |
| rs58381381 | chr22:32893524:T:C | - | 0.207403061948876 | 0.0027092749277305 | BLCA | Female-baised eQTL |
| rs9621573 | chr22:32831512:T:C | - | 0.198037815081414 | 0.00291407865011711 | BLCA | Female-baised eQTL |
| rs62234166 | chr22:32880487:G:A | - | 0.206408440292222 | 0.00299481839658104 | BLCA | Female-baised eQTL |
| rs62234167 | chr22:32885515:C:T | - | 0.196230037776718 | 0.00648874643888073 | BLCA | Female-baised eQTL |
| rs130517 | chr22:33954476:A:T | - | 0.151920187944242 | 0.00783789608229122 | BLCA | Female-baised eQTL |
| rs137509 | chr22:32888234:T:G | - | -0.188265602456018 | 0.00913512995789708 | BLCA | Female-baised eQTL |
| rs74438510 | chr22:32842162:C:G | - | 0.190452274954529 | 0.0098460302965221 | BLCA | Female-baised eQTL |
| rs137530 | chr22:32902776:T:A | - | -0.183068410724529 | 0.0125697389407142 | BLCA | Female-baised eQTL |
| rs80693 | chr22:32904362:G:T | - | -0.183068410724529 | 0.0125697389407142 | BLCA | Female-baised eQTL |
| rs73181704 | chr22:48927552:G:C | - | 0.240138190069619 | 0.0129803085349929 | BLCA | Female-baised eQTL |
| rs16992933 | chr22:44837838:T:C | - | 0.155416625948756 | 0.0131398603108328 | BLCA | Female-baised eQTL |
| rs6518799 | chr22:32833610:G:A | - | 0.171698207755565 | 0.0135820747253897 | BLCA | Female-baised eQTL |
| rs11089595 | chr22:32834363:G:A | - | 0.171698207755565 | 0.0135820747253897 | BLCA | Female-baised eQTL |
| rs9621575 | chr22:32834806:G:A | - | 0.171698207755565 | 0.0135820747253897 | BLCA | Female-baised eQTL |
| rs8142143 | chr22:32835400:G:A | - | 0.171698207755565 | 0.0135820747253897 | BLCA | Female-baised eQTL |
| rs8142834 | chr22:32836560:T:C | - | 0.171698207755565 | 0.0135820747253897 | BLCA | Female-baised eQTL |
| rs8136803 | chr22:32841125:G:T | - | 0.171698207755565 | 0.0135820747253897 | BLCA | Female-baised eQTL |
| rs137525 | chr22:32900153:C:T | - | -0.181431965034591 | 0.0154464650244296 | BLCA | Female-baised eQTL |
| rs5754684 | chr22:33806827:A:T | - | -0.167691971166772 | 0.0171266080923752 | BLCA | Female-baised eQTL |
| rs8140818 | chr22:32832736:T:C | - | 0.164432170083729 | 0.0225327086718576 | BLCA | Female-baised eQTL |
| rs5994625 | chr22:32772576:A:G | - | -0.154986779125742 | 0.0226566650418746 | BLCA | Female-baised eQTL |
| rs5998634 | chr22:32773129:T:C | - | -0.154986779125742 | 0.0226566650418746 | BLCA | Female-baised eQTL |
| rs135150 | chr22:32774115:C:T | - | -0.154986779125742 | 0.0226566650418746 | BLCA | Female-baised eQTL |
| rs130531 | chr22:32774697:T:C | - | -0.154986779125742 | 0.0226566650418746 | BLCA | Female-baised eQTL |
| rs9609889 | chr22:33944873:G:A | - | 0.143122596768448 | 0.0230481157498946 | BLCA | Female-baised eQTL |
| rs130297 | chr22:32829965:T:C | - | -0.162689891647312 | 0.0243475752670454 | BLCA | Female-baised eQTL |
| rs5749668 | chr22:33808216:C:T | - | -0.17000121581084 | 0.0273399620204164 | BLCA | Female-baised eQTL |
| rs738942 | chr22:33793266:T:C | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs2413200 | chr22:33795963:T:C | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs2018743 | chr22:33796438:C:A | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs5754676 | chr22:33797078:C:T | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs722659 | chr22:33797847:C:T | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs2413201 | chr22:33799185:G:A | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs867124 | chr22:33799353:C:G | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs5749665 | chr22:33800521:T:C | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs5754679 | chr22:33801380:T:C | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs5754682 | chr22:33806297:C:T | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs5999109 | chr22:33806783:A:G | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs2899213 | chr22:33807250:C:T | - | -0.166334912572589 | 0.0315429983752833 | BLCA | Female-baised eQTL |
| rs1811104 | chr22:33787018:T:C | - | -0.167558311080361 | 0.0338900977867209 | BLCA | Female-baised eQTL |
| rs238859 | chr22:33761827:T:C | - | -0.159183810999309 | 0.0358979473810767 | BLCA | Female-baised eQTL |
| rs173237 | chr22:33764145:A:G | - | -0.159183810999309 | 0.0358979473810767 | BLCA | Female-baised eQTL |
| rs424576 | chr22:33765041:C:T | - | -0.159183810999309 | 0.0358979473810767 | BLCA | Female-baised eQTL |
| rs424784 | chr22:33765121:C:T | - | -0.159183810999309 | 0.0358979473810767 | BLCA | Female-baised eQTL |
| rs446869 | chr22:33765731:T:C | - | -0.159183810999309 | 0.0358979473810767 | BLCA | Female-baised eQTL |
| rs28374 | chr22:33770152:T:C | - | -0.159183810999309 | 0.0358979473810767 | BLCA | Female-baised eQTL |
| rs130523 | chr22:33957265:T:C | - | 0.127505713568179 | 0.0371854775085777 | BLCA | Female-baised eQTL |
| rs137507 | chr22:32886984:T:C | - | -0.164946579122513 | 0.0373068020294705 | BLCA | Female-baised eQTL |
| rs4452 | chr22:32887270:T:C | - | -0.164946579122513 | 0.0373068020294705 | BLCA | Female-baised eQTL |
| rs137522 | chr22:32897922:T:C | - | -0.164946579122513 | 0.0373068020294705 | BLCA | Female-baised eQTL |
| rs447318 | chr22:33765502:A:G | - | -0.158817990810392 | 0.0374068654426913 | BLCA | Female-baised eQTL |
| rs130296 | chr22:32829037:C:T | - | -0.156528438195059 | 0.0376377004397585 | BLCA | Female-baised eQTL |
| rs1811103 | chr22:33786902:A:T | - | -0.163370489141522 | 0.041459587625159 | BLCA | Female-baised eQTL |
| rs5766366 | chr22:45052036:T:C | - | 0.134872499002571 | 0.0423333044809417 | BLCA | Female-baised eQTL |
| rs130535 | chr22:32779485:C:G | - | -0.154203059542518 | 0.04294468208213 | BLCA | Female-baised eQTL |
| rs73158348 | chr22:32842120:G:T | - | 0.165800451901394 | 0.0434572457183201 | BLCA | Female-baised eQTL |
| rs73158349 | chr22:32842121:A:T | - | 0.165800451901394 | 0.0434572457183201 | BLCA | Female-baised eQTL |
| rs113989936 | chr22:45490221:C:T | - | 0.181222086096295 | 0.0470307848941647 | BLCA | Female-baised eQTL |
| rs2236031 | chr22:50483265:C:T | - | 0.077969835670815 | 0.0279186839426173 | COAD | Female-baised eQTL |
| rs135224 | chr22:49116841:C:T | - | 0.0740213843709719 | 0.0482692063181848 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs199509869 | chr22:34749533:G:T | - | 0.097002373039291 | 0.0091237574822278 | COAD | Male-baised eQTL |
| rs60203296 | chr22:34825615:C:A | - | 0.0720686099015746 | 0.0142455410687984 | COAD | Male-baised eQTL |
| rs9607469 | chr22:37523260:G:A | - | 0.0754026354803836 | 0.0314419051710103 | COAD | Male-baised eQTL |
| rs5757550 | chr22:39205214:T:C | - | -0.0480360719923431 | 0.0421608922346145 | COAD | Male-baised eQTL |
| rs150559438 | chr22:39217678:A:G | - | 0.0492667280812337 | 0.0433180391142621 | COAD | Male-baised eQTL |
| rs130655 | chr22:39216694:C:T | - | 0.0479801920338984 | 0.0451274549876256 | COAD | Male-baised eQTL |
| rs2413581 | chr22:39209002:T:C | - | -0.0471550281671234 | 0.0454640815066076 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000235568 |
| CpG Site: cg03365751 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: - | |
| Female Effect: -0.302092705682079 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg03365751 | chr22:42432380 | gene,exon,promoter,UTR | -0.302092705682079 | 1.77252195648406e-08 | -0.4140831831406717 | 2.480217681799448e-07 | SARC |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of NFAM1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
